The Correlation between Aberrant Promoter Methylation of MGMT and Immunohistochemical Expression with Clinical Prognosis in Glioblastoma Multiforme

Gong CHEN,Xing WU,Rong XIE,Ying MAO

DOI: https://doi.org/10.3969/j.issn.1008-0678.2017.02.002

2017-01-01

Abstract:Aim To explore the correlation between the methylation status of MGMT promoter and MGMT protein expression levels in GBM and patients' survival,determine the methylation status of the MGMT promoter and the MGMT protein expression in gliomas,and analyze the correlation between MGMT methylation status and patients' outcome.Methods 119 formalin-fixed and paraffin-embedded GBM tissue samples were obtained after informed consent from adult patients.Genomic DNA was extracted and MGMT methylation status was measured with MethyLight assay after bisulfite treatment.The protein expression levels of MGMT were determined by immunohistochemical staining.The correlation between MGMT methylation status and MGMT expression levels was measured with Chi-square test,and the correlation between patients' outcome and MGMT methylation status or MGMT expression levels was determined by log-rank tests.Results The MGMT promoter was found to be methylated in 35.3％ patients (42/119).A significant correlation was observed between MGMT promoter methylation and patients' survival (PFS,P=0.011 and OS,P=0.036).No correlation was found between MGMTpromoter methylation and MGMT expression determined by immunohistochemical staining (P＞0.05),nor MGMT expression and patients' survival (P＞0.05).Conclusion The results supported that MGMT promoter methylation status may be more suitable as a predictive biomarker than the MGMT expression in the treatment of patients with GBM.